More research feature articles

The impact of COVID-19 on clinical trials

As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting

Addressing the payer-regulator evidence gap in early-stage cancer

By Jason Ward

Health trust in a COVID-19 world – a unique opportunity for pharma

The COVID-19 pandemic is a pivotal moment and, for some within the healthcare sector, this could be a once-in-a-generation opportunity to change the narrative

Why blood donors and a solid national blood bank are vital

By Haifa Ungapen

A snapshot of… Enterprise Therapeutics

AI and genomics: a revolution in drug discovery and development

Working together against COVID-19

Analysing social media conversations to see what HCPs are saying online about the global pandemic

The big issue

Whether you want to lead or follow, you need to understand the elephant in the C-suite

COVID-19: the race to find a vaccine

How biopharma is working to bring an end to the pandemic

Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy

Global product lead George Kirk hails the triumph of selumetinib, which has just won FDA approval

Risks, reforms and rewards: the evolving Russian healthcare market

While reforms introduced in the past two decades have brought stability and sought to address some of the structure issues, problems remain

Biopharma and orphan drugs

Rare disease drug approvals are improving, thanks to regulatory support

GSK forges ahead with its dynamic COPD and asthma portfolio

A landmark year of discovery and development in COPD brings hope to millions of patients

COVID-19 hits supply chains

Swift advance of virus exposes US pharma’s over-reliance on China

Developing a COVID-19 vaccine

The pharma industry ramps up its efforts as case numbers continue to rise

As COVID-19 takes over the world, biopharma fights back

Biopharma companies across the world unite in the race to find an effective COVID-19 treatment

Cortellis Drugs to Watch in 2020 report

The latest Cortellis Drugs to Watch report highlights medicines that treat high prevalence conditions